Keystone Heart
Embolic Cerebral Protection Devices
Company Overview
Snapshot
Founded in November 2004, Keystone Heart operates with 11–50 employees. The company secured funding across one disclosed round, with OrbiMed participating. A significant milestone occurred in December 2018 when Keystone Heart was acquired by Venus Medtech.
Business overview
Keystone Heart is a medical device company specializing in the development and manufacturing of cerebral embolic protection devices. Its core technology, the TriGuard product pipeline, aims to mitigate the risk of stroke, neurocognitive decline, and dementia by protecting the brain from emboli during cardiovascular procedures such as TAVR, surgical valve replacement, and atrial fibrillation ablation. The company serves interventional cardiologists, electrophysiologists, and cardiac surgeons within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment & therapeutics.
Strategic signal
In March 2020, Keystone Heart secured the CE Mark for its cerebral embolic protection device, a critical regulatory approval that validates the device's safety and performance for the European market. This achievement signals the company's commitment to expanding its market reach and providing its technology to a broader patient population, reinforcing its position in the medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant corporate development for Keystone Heart in late 2018?
- In December 2018, Keystone Heart was acquired by Venus Medtech, marking a key exit for the company.
- Which company did Keystone Heart acquire in 2020?
- In June 2020, Keystone Heart, as a Venus Medtech company, acquired 510 Kardiac Devices, Inc.
- When did Keystone Heart announce the first commercial case worldwide with its TriGUARD 3 device?
- In July 2020, Keystone Heart, a Venus Medtech company, announced the first commercial case performed worldwide with the TriGUARD 3 Cerebral Embolic Protection Device.
- What regulatory milestone did Keystone Heart achieve in 2020?
- In March 2020, Keystone Heart secured the CE Mark for its cerebral embolic protection device, allowing its commercialization in Europe.
- When did Keystone Heart begin a Phase II trial for its TriGUARD 3 device?
- In June 2018, Keystone Heart began a Phase II trial for its TriGUARD 3 device.